Evidence question
Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026
Bottom line
Levothyroxine is standard first-line therapy with the strongest outcome evidence. Desiccated thyroid extract lacks modern RCT data demonstrating superiority and has variable hormone content between batches.[1–6]
Evidence confidence
Evidence Confidence
HighMultiple high-quality studies directly address this question, with generally consistent findings.
Key uncertainty. Patient preference and symptom-based NDT use outpace randomized outcome evidence; batch variability complicates dose standardization.
Ask RAGMD
Get the live evidence synthesis
10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.
Randomized trials comparing desiccated thyroid extract (Armour) to levothyroxine (Synthroid) show no consistent advantage for either on most patient-reported outcomes. A minority of patients report preference for combination therapy.
Yes — desiccated thyroid extract contains both T4 and T3. This results in higher and more variable T3 levels compared to levothyroxine alone, which some consider physiologically preferable.
Levothyroxine provides T4, which peripherally converts to T3. Desiccated thyroid delivers both hormones but at a fixed ratio that may not match every patient's conversion needs. Levothyroxine plus separate T3 offers more precise titration.
Patients with persistent hypothyroid symptoms on optimized levothyroxine may be candidates for a trial of desiccated thyroid or combination T4/T3 therapy, following shared decision-making and specialist review.
Levothyroxine is standard first-line therapy with the strongest outcome evidence. Desiccated thyroid extract lacks modern RCT data demonstrating superiority and has variable hormone content between batches.
Levothyroxine is standard first-line therapy with the strongest outcome evidence. Desiccated thyroid extract lacks modern RCT data demonstrating superiority and has variable hormone content between batches.
At a glance
| Dimension | Desiccated Thyroid (Armour / NP Thyroid) | Levothyroxine (Synthroid / generic) |
|---|---|---|
| Hormones contained | T4 + T3 (fixed ~4:1 T4:T3 ratio) | T4 only; peripheral conversion to T3 |
| T3 levels on therapy | Higher, more variable T3; T3 peak after dose | Stable T3 from peripheral conversion |
| RCT evidence | No consistent advantage on symptoms in RCTs vs LT4 | Extensive RCT base; standard-of-care comparator |
| Guideline recommendation | Alternative option for patients with persistent symptoms on LT4 | First-line treatment per ATA, ETA, and most society guidelines |
| Patient preference | Minority of patients report subjective preference | Most patients achieve adequate replacement |
Landmark studyPMID 41938307
LT4 monotherapy is overwhelmingly employed as first line therapy for hypothyroidism by U.S. However, the high usage of thyroid hormones for patients whose symptoms were considered to be unrelated to hypothyroidism is at odds with current international guidelines for the management of hypothyroidism.
Landmark studyPMID 28402245
Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126 .).
Landmark studyPMID 23428746
c-Jun N-terminal kinases (JNKs) are central and ubiquitous mediators of cellular signaling for both physiogical-regenerative and pathological-apoptotic processes. Their impact on degeneration or inflammation is well documented, but so far little is known about their roles in higher brain functions.
Landmark studyPMID 38260143
Primary hypothyroidism affects about 3% of the general population in Europe. Early treatments in the late 19 th Century involved subcutaneous as well as oral administration of thyroid extract.
1 additional landmark study linked to this question.
Additional treatment strategies for hypothyroidism: a network meta-analysis.
Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials.
L-Thyroxine Therapy for Older Adults With Subclinical Hypothyroidism and Hypothyroid Symptoms: Secondary Analysis of a Randomized Trial.
+3 more
More in this focus area
Other structured clinical questions in Thyroid.
Does combination T3/T4 therapy improve symptoms versus levothyroxine alone?
Randomized trials and meta-analyses show inconsistent symptom benefit from adding liothyronine to levothyroxine compared with levothyroxine monotherapy. Guidelines generally recommend levothyroxine as first-line therapy.
11 linked studies
Should subclinical hypothyroidism be treated with levothyroxine?
The TRUST trial found no meaningful symptom or quality-of-life benefit from levothyroxine in older adults with subclinical hypothyroidism. Treatment may still be considered with very high TSH, pregnancy plans, or specific clinical contexts.
11 linked studies
What TSH target is appropriate for treated hypothyroidism?
Most guidelines suggest maintaining TSH within the reference range on levothyroxine, often near the lower half for many patients. Pregnancy and specific comorbidities require tighter targets.
11 linked studies
Does treated hypothyroidism fully explain difficulty losing weight?
Hypothyroidism can contribute to weight gain, but levothyroxine normalization typically yields modest weight loss rather than resolving obesity. Persistent weight difficulty usually involves additional metabolic and behavioral factors.
11 linked studies
Go deeper on Thyroid
Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.
